Dyne Therapeutics, Inc.
DYN · XNASCIK 1818794fmd_0EKMKG2DW412J7THMB7WCVECYBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | 11 | 45 | 121 | 143 | 211 | 281 | 398 |
| Total operating expenses | 14 | 59 | 150 | 171 | 242 | 344 | 468 |
| Compensation and benefits | – | – | – | 35 | 49 | 63 | 86 |
| Operating income | (14) | (59) | (150) | (171) | (242) | (344) | (468) |
| Other non-operating income (expense) | (1) | (1) | 1 | 3 | 6 | 26 | 22 |
| Income tax expense | – | – | – | – | 0 | 0 | 0 |
| Net income | (15) | (59) | (149) | (168) | (236) | (317) | (446) |